The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown. To identify genetic risk factors for and novel characteristics of secondary leukemia, we profiled 116 204 single nucleotide polymorphisms (SNPs) in germline and paired leukemic cell DNA from 13 secondary leukemia/myelodysplasia cases and germline DNA from 13 matched and 156 unmatched controls, all with acute lymphoblastic leukemia treated with etoposide. We analyzed global gene expression from a partially overlapping cohort. No single locus was altered in most cases. We discovered 81 regions of loss of heterozygosity (LOH) in leukemic blasts and 309 SNPs whose allele frequencies differed in cases vs controls. Candidate genes were prioritized on the basis of genes whose SNPs or expression differentiated cases from controls or showed LOH or copy number change in germline vs paired blast DNA from the13 cases. Three biological pathways were altered: adhesion, Wnt signaling and regulation of actin. Validation experiments using a genome scan for etoposideinduced leukemogenic MLL chimeric fusions in 15 HapMap cell lines also implicated genes involved in adhesion, a process linked to de novo leukemogenesis. Independent clinical epidemiologic and in vitro genome-wide approaches converged to identify novel pathways that may contribute to therapyinduced leukemia.
Introduction
Second cancers account for almost 10% of all malignancies in the United States. 1 One of the most serious second cancers is therapy-related leukemia or myelodysplasia, which we refer to collectively as secondary leukemia. [2] [3] [4] Treatment-related factors have been identified that contribute to the development of secondary leukemia, including use of epipodophyllotoxins, such as etoposide, and alkylating agents. [5] [6] [7] [8] [9] [10] However, the genetic factors that place patients at risk of secondary leukemia remain largely unknown. DNA-based candidate gene approaches have identified few, poorly penetrant genetic risk factors. 11, 12 While high-throughput whole-genome methods can now better characterize the genetics of many de novo cancers, [13] [14] [15] they have not been applied to secondary cancers.
We conducted clinical and laboratory-based genome-wide studies to profile secondary leukemia. For our clinical studies, we compared 116 204 single nucleotide polymorphisms (SNPs) in germline vs secondary leukemia blast DNA (Figure 1 ), and germline SNPs in cases of secondary leukemia vs identically treated controls. The DNA polymorphism data were merged with genome-wide microarray expression data from a separate, partially overlapping cohort of cases and controls 16 to identify high-risk pathways associated with secondary leukemia. For our experimental studies, we conducted a genome-wide survey of polymorphisms that predict the in vitro formation of leukemogenic chromosomal translocations. Over 75% of cases of epipodophyllotoxin-induced secondary leukemia are characterized by chromosomal translocations caused by the chimeric fusion of the MLL gene with any one of a number of partners. 17 These MLL fusions are leukemogenic in vivo [18] [19] [20] and can be induced experimentally in vitro with etoposide. 21, 22 We capitalized on the availability of over a million SNP genotypes from human lymphoblastoid cell lines that constitute a subset of the International HapMap Project samples, to identify genes associated with etoposide-induced MLL fusions in vitro.
These two independent genome-wide approaches, clinical epidemiologic studies of patients and experimentally induced leukemogenic MLL fusions in HapMap cell lines, converged to reveal cellular adhesion pathways disrupted in secondary leukemia.
Materials and methods

Patients and samples
All patients were children with acute lymphoblastic leukemia (ALL) treated on protocols Total XIIIA and XIIIB at St Jude Children's Research Hospital, both of which included etoposide. Parents and patients gave informed consent and assent, and the protocols and analyses were approved by the Institutional Review Board. Details of the therapeutic regimens and diagnostic procedures have been published previously. 7, 23 Briefly, diagnostic bone marrow was examined by cytogenetic analysis for all patients; for Total XIIIA, bone marrow DNA was evaluated by Southern blot for MLL rearrangements, and for Total XIIIB, the RNA was screened for the MLL/AF4 fusion transcript by reverse-transcriptase polymerase chain reaction (PCR). Patients were followed at least 10 years from the start of therapy. Patients with a history of ALL who subsequently developed secondary leukemia (cases) and patients with ALL who were treated similarly but did not develop secondary leukemia (controls) (Figure 1 ) were compared. Herein, we studied all 13 of the 20 previously reported cases who had adequate germline and secondary leukemia blast DNA samples available. 7 Among the 13 cases, nine presented with secondary myeloid leukemia, three with myelodysplastic syndrome and one with secondary ALL, as previously described. 7 We use the term 'secondary leukemia' to refer to these 13 cases throughout. Race was self-reported. Twelve of the cases and 12 of the controls were Caucasian (one each was African-American) and had a history of B-lineage ALL (one each had T-cell ALL). The median age in the cases and primary matched controls was 7.2 (1.7-16.7) and 5.2 (0.9-12.7) years, respectively. The median onset of secondary leukemia was 3.7 years from diagnosis of ALL. Ten cases (77%) exhibited MLL rearrangements involving chromosome 11q23 (Table 1) , consistent with etoposide-induced secondary leukemia. [2] [3] [4] The primary control group comprised 13 patients who were matched to the cases on the basis of use of granulocyte colony stimulating factor, prescribed etoposide dose, irradiation, ALL risk classification and race. A secondary control group comprised all other children on Total XIIIA and XIIIB who had germline DNA available for genome-wide analysis (n ¼ 156), in addition to the 13 matched controls, for a total of 169 controls.
Germline DNA was extracted from normal leukocytes of the cases and controls collected after each had achieved initial remission of their ALL. At the time of diagnosis of secondary leukemia, bone marrow was cryopreserved and DNA was extracted at a later date (case blast sample). The median blast percentage of the case blast samples, as determined by immunophenotyping of the primary bone marrow aspirate, was 78% (range 6-98%). Only one case (Table 1 , case 1) had o40% blasts.
We previously compared global gene expression profiles of diagnostic ALL blasts in patients who did vs did not develop secondary leukemia, which included nine of the 13 secondary leukemia cases and 10 of the 13 matched controls reported herein. 16 Genotyping DNA (500 ng) was digested with XbaI and HindIII restriction enzymes, amplified, labeled and hybridized to the Affymetrix GeneChip Human Mapping100K Set according to the manufacturer's instructions. The chips were scanned, and genotype calls were made using GeneChip DNA Analysis Software. All but two samples ( 
Data analysisFoverview
We compared results within and between patients (Figure 1 ). We analyzed LOH and copy number differences by comparing germline DNA to secondary leukemic blast DNA for each case to identify possible additional acquired genomic abnormalities of secondary leukemia. We compared the germline samples from the cases to those from the matched controls to assess allele frequency differences that might indicate inherited genomic susceptibility to secondary leukemia. We also compared allele frequencies in the larger group of controls (n ¼ 169) to allele frequencies in the 13 cases. We compared ALL blast gene expression from microarrays in cases vs controls (as previously reported), 16 as variation in gene expression is partially reflective of germline genomic variability, 24, 25 which could reflect inherited susceptibility to secondary leukemia.
Case -control analysis
For eight of the 13 case -control pairs, sex was not matched, and thus the sex chromosomes were excluded. Because the controls were not exactly matched to cases on all features, we regarded cases and controls as two independent samples. SNPs were filtered out if they were invariant among all samples, or if they had less than a 100% call rate, leaving a total of 64 373 SNPs. We used the Wilcoxon rank sum test 26 to determine allele frequency differences between cases and controls.
Loss of heterozygosity
For each case we generated a call of LOH, retention or indeterminate for each SNP by comparing the germline and case blast genotypes, as described by Lin et al. 27 To define regions of LOH within each case, we used the positions of SNPs with LOH calls to divide the genome into segments. We utilized a simulation-based approach to compute a P-value for each segment, representing a test of whether the observed number of retention calls in each segment was fewer than would be expected under a specific model of randomness. We estimated the conditional false discovery rate 28 and total error criterion as a function of the P-value threshold used to determine significance, and combined bordering significant segments to infer regions of LOH (Supplementary Information).
Copy number differences
To detect regions of difference in chromosome copy number between each case blast and paired germline sample, we normalized the overall signal intensities for each chip, and used a change-point model implemented in the DNAcopy package (Supplementary Information). A segment was considered to have a copy number increase if the estimate was 41, using the 25th percentile of the ratios of blast/germline signal, and a copy number decrease if the estimate was o1, using the 75th percentile of the signal intensity ratios. Figure 1 An overview of the study design. For the case -control analysis, allele frequencies were compared in germline DNA from secondary leukemia cases (t-ML) vs similarly treated controls; allele frequencies were also compared in germline DNA from cases vs a larger control group (n ¼ 169). LOH and copy number analyses used comparisons of SNP calls between the germline DNA and the secondary leukemia blast DNA of each case. LOH, loss of heterozygosity; SNP, single nucleotide polymorphism.
Genome-wide study of secondary leukemia C Hartford et al Table 1 Summary of cytogenetics of case blast samples and primary ALL blast samples for each case, number of SNPs with identical genotypes in blast and germline, regions of LOH and copy number differences in case blast vs paired case germline samples 50 was estimated for each cell line. The formation of etoposide-induced MLL fusions was analyzed for a subset of the most sensitive (n ¼ 11) and resistant (n ¼ 4) cell lines, based on the IC 50 of each cell line (Supplementary Table 2 ). Cells were seeded at 0.5 Â 10 6 cells/ml and at 24 h treated with dimethylsulfoxide (control) or etoposide at a concentration 10 times the estimated IC 50 value for that cell line. After 8 h, cells were collected, DNA extracted and MLL rearrangements measured using a modification of our previous method. 21 The number of PCR amplicons corresponding to MLL chimeric fusions after etoposide exposure, relative to control, was determined for each cell line (www.pharmgkb.org PS207017) (Supplementary Table 2 ).
Genotype data for 1 105 064 SNPs in these cell lines were available from the International HapMap Project (www.hapmap. org), release 19. Using human genome assembly NCBI build 35, SNPs were mapped to annotated genes within 5000 bp. Linear regression was used to determine the correlation between SNP genotype and the number of MLL rearrangements. Those genes with SNPs for which there was an association at the Po0.01 level were used for pathway analysis.
Gene and pathway analysis
We prioritized genes on the basis of SNPs whose allele frequency differed in cases vs controls, or that demonstrated LOH or copy number differences in germline vs blast DNA, assigning SNPs to genes within 5000 bp. We combined these genes with those from our previous analysis of genes whose expression differentiated cases from controls. 16 We queried the KEGG database 31 to determine which pathways were overrepresented by genetic alteration in cases of secondary leukemia. Independently, we performed a pathway analysis on the basis of genes from our experiments in cell lines whose SNP frequencies predicted high levels of etoposide-induced MLL rearrangements.
Validation
We compared the biological pathways that were overrepresented on the basis of a genome-wide analysis of the clinical samples (distinguishing secondary leukemia cases vs controls), with those that were overrepresented on the basis of genomewide analysis of the treated cell lines (distinguishing high vs low levels of etoposide-induced MLL rearrangements). We sequenced several SNPs whose allele frequencies differed in cases vs controls to confirm genotypes. We also used real-time PCR to confirm the presence of increased copies of the region of 14q11.2 that was found to have increased copy number in several of the case blast/germline pairs by SNP analysis (Supplementary Information).
Results
Cases vs controls
By comparing the germline DNA from cases to the germline DNA from controls, the inherited genomic differences between those who develop and those who do not develop secondary Table 3 ). When we compared the 13 cases to the larger cohort of control patients (n ¼ 169), 168 out of the 309 SNPs identified were found to have a significant difference in allele frequency (Po0.05). We also limited our analysis to the 10 cases exhibiting MLL rearrangements and their 10 matched controls, and found that 280 of the 309 SNPs showed significant differences in allele frequency (Po0.05).
Acquired genomic abnormalities in secondary leukemia cases
As expected, the secondary leukemia blasts displayed completely different karyotypes than the diagnostic ALL blasts. By comparing the germline DNA from each case to the DNA from the paired secondary leukemia blasts, acquired genomic abnormalities beyond those detected with conventional cytogenetics might be identified. These genomic abnormalities may help to further elucidate the pathogenic mechanisms that contribute to the development of secondary leukemia, and thus may be helpful in identifying potential risk factors. Although the predominant chromosomal defect in secondary leukemia cases was a balanced 11q23 translocation, three cases had a total of five areas of chromosome loss identified cytogenetically, all of which were detected by SNP analysis as significant regions of LOH (Figure 2 ; Table 1 ). Thus, the utility of SNP analyses in detecting gross copy number changes was confirmed. In addition, there were 76 cryptic regions of LOH (as defined in Materials and methods and in the Supplementary Information) detected by SNP analysis that were not detected cytogenetically (Table 1) .
There were a total of 21 regions of decreased and 18 regions of increased copy number in the secondary leukemic blasts relative to the germline detected among nine cases (Table 1) . Three levels of evidence validated the copy number findings. First, the increased copies of 14q11.2 noted in five cases were validated by real-time PCR (Supplementary Information). Second, all regions of cytogenetically detected loss (Table 1, cases 3, 5, 9) were detected as regions of decreased copy Genome-wide study of secondary leukemia C Hartford et al number using the SNP data. Third, even one of the cases with a low call rate (Table 1 , case 1) had a loss of 6p cytogenetically, and this was also detected as decreased copy number in chromosome 6 (data not shown), despite the low SNP call rate as well as a low percent (6%) of blasts in the secondary leukemia sample.
Analysis of cell lines
Experimentally, we found that MLL rearrangements in 15 human lymphoid cell lines (Supplementary Table 2) were significantly (Po0.0001) more common after etoposide treatment compared to untreated control. The number of MLL rearrangements did not differ in sensitive compared to resistant cell lines (P ¼ 0.9), suggesting that the formation of leukemogenic MLL fusions was unrelated to inherent etoposide sensitivity. Using publicly available SNPs typed in these lines (www.hapmap.org), 2217 genes had SNPs whose allele frequency predicted levels of MLL rearrangement (Po0.01) (Figure 3 ).
Pathway analysis
Overall, there was no recurring SNP or gene involved in the majority of secondary leukemia cases. We hypothesized that there might be common pathways whose genes are 'hit' by various mechanisms (that is, LOH, increased or decreased copy number or expression, or germline genotypes), with an ultimate functional consequence that could lead to secondary leukemia. Genes that distinguished cases from controls identified from SNP and gene expression analyses included 1695 genes, and each was classified as to the method by which it had been invoked (that is, allele frequency differences in cases vs controls, LOH or copy number differences in secondary leukemia blasts vs germline, or via gene expression differences 16 ). For each gene, we tabulated the number of cases harboring the 'high-risk' genotype associated with the development of secondary leukemia (Supplementary Table 3 ). A subset of 414 of these 1695 genes was considered to have stronger evidence, based on the gene being invoked by at least two levels of evidence and being involved in a minimum of four cases.
We queried the KEGG database 31 to identify pathways that most frequently encompassed these genes (Supplementary Table 4) .
Focal adhesion was a highly ranked pathway along with two pathways that directly interact with it, namely regulation of actin cytoskeleton and Wnt signaling (Figure 4; Supplementary Figure 1) . Relatively few discriminating genes are required to invoke these three inter-related pathways in most of the cases (Table 2) : RAPGEF1, CCND1 and FLNA (focal adhesion, affecting nine cases); MYL1, ARHGEF7 and TIAM1 (actin cytoskeleton, affecting all 13 cases); and CCND1, NFATC4, PPP2CA and PPP2R2A (Wnt signaling, affecting 10 cases). Several of these genes also play more direct roles in cell cycle regulation and apoptosis ( Table 2 ). All 13 secondary leukemia cases had abnormalities in one or more of these pathways. Moreover, we performed a pathway analysis on the basis of the 10 cases exhibiting 11q23 rearrangements (Table 1) , which correspond to the clinical MLL rearrangements that etoposide causes in vitro (see below), and found that the focal adhesion pathway was also invoked and highly ranked (data not shown).
Independently, we performed a pathway analysis based on experiments of etoposide-induced gene rearrangements in 15 HapMap cell lines, including the 2217 genes with SNPs significantly associated with the number of etoposide-induced MLL fusions. Again, focal adhesion was the highest-ranked pathway that was over-represented (Supplementary Table 4 ). Because MLL gene rearrangements are the most frequent characteristic of secondary leukemia, [2] [3] [4] these experimental data support the clinical genome-wide epidemiologic data implicating aberrations in focal adhesion in secondary leukemia.
Discussion
Our findings suggest a small group of genes and novelly invoked pathways that play a role in the development of secondary leukemia. Although most secondary leukemia blasts are characterized by an invariant molecular lesion (that is, rearrangement of MLL with 11q23 translocations), [2] [3] [4] whether there are additional acquired germline genomic variations that predispose to this mechanism of leukemogenesis has not been clear. To identify predisposing genetic factors, we combined two clinical epidemiological genome-wide approaches: mapping arrays to interrogate SNPs and microarrays to evaluate gene expression. By comparing germline DNA from patients who Figure 3 An overview of independent validation analysis using International HapMap cell lines. Using 15 HapMap lymphoblastoid cell lines, the SNPs whose genotypes significantly predicted the level of etoposide-induced MLL gene fusions were used to independently identify genes and pathways (Supplementary Table 4 ) associated with leukemogenic processes in vitro. The relationship between leukemogenic MLL rearrangements and germline genotype for a significantly (P ¼ 0.005) associated SNP (rs2006710) in TIAM1 is illustrated in the box plot; this gene was also among the top-ranked genes in the analysis of patients with secondary leukemia (Figure 4 ; Table 2 ). SNP, single nucleotide polymorphism. Figure 4 Pathways disrupted in secondary leukemia. The pathway depicts the relationship among genes that were disrupted in cases of secondary leukemia in the focal adhesion (yellow), regulation of actin cytoskeleton (blue) and Wnt signaling (green) pathways. Genes could be invoked by one or more methods based on results of the SNP chip analyses (CC, case -control allele frequency differences; LOH, loss of heterozygosity or CN, copy number differences in paired germline vs secondary leukemia blast samples), or from results of a complementary study of gene expression (GE), as illustrated in the Venn diagram. SNP, single nucleotide polymorphism.
Table 2
Top-ranked pathways invoked by genes involved in expression differences, allele frequency differences, LOH or copy number differences, and the discriminating genes required to invoke the pathway in the indicated number of cases 
12
A Rho guanine nucleotide exchange factor that acts on RAC1. Mutations in TIAM1 have been associated with renal cell carcinoma. 37 Increased expression has been shown in acute myeloid blasts from patients with Down syndrome. 38 Wnt signaling CCND1 6 Involved in cell cycle progression. Abnormalities of cyclin D1 result in changes in the duration of G1 phase of the cell cycle and have been reported in a number of cancers. developed secondary leukemia to germline DNA from patients who were similarly treated for ALL and did not develop secondary leukemia, possible genetic risk factors for secondary leukemia were identified. By comparing germline to leukemic blast DNA from patients who developed secondary leukemia, potential pathogenic mechanisms of secondary leukemia may be identified. Gene expression differences in cases vs controls 16 may also reflect germline genetic variation that could predispose to secondary leukemia. We found a number of genetic abnormalities, which tended to cluster in a few specific biological pathways: focal adhesion, regulation of actin cytoskeleton and Wnt signaling. Interestingly, using an independent but complementary experimental genome-wide approach, these same pathways were highly ranked among genes whose SNP genotype frequencies predicted the extent of MLL rearrangements generated in vitro.
Candidate gene approaches have attempted to identify host factors that may explain why some patients treated with conventional anticancer drugs develop a second cancer while others seem to be protected. The concept of individualized medicine is based on the premise that inter-individual genetic variability will identify 'at risk' subtypes of patients. Our data suggest that there are likely to be combinations of defects in different genes, all affecting the same biological pathway, which together collaborate to define patient subsets. A major challenge in making genetically based medicine a reality will be to tease out such multi-gene pathways prospectively to allow for individualized medication regimens.
Focal adhesions between a cell and its extracellular environment physically link the extracellular matrix to the inside of the cell, facilitating intracellular signaling processes. 41 Normal hematopoietic progenitors possess a variety of adhesion molecules 42 that maintain physical localization of hematopoietic progenitors within bone marrow stroma, thereby regulating growth, differentiation and migration of hematopoietic cells. [43] [44] [45] Abnormal adhesion has been linked to leukemia, 43 with up to 85% of ALL samples having a defect in integrin-mediated adhesion. Whereas decreased adhesion to marrow stroma was postulated to lead to premature release of myeloid leukemia progenitor cells into the periphery, 46 ,47 the presence of the BCR-ABL fusion has also been associated with increased adhesion. 48, 49 In patients with secondary leukemia, it is possible that defects in adhesion promote resistance to apoptosis and the acquisition of drug-induced sublethal DNA damage in hematopoietic stem cells, such as the drug-induced MLL rearrangements we demonstrated experimentally. Adhesion molecules protect against etoposide-induced apoptosis, 50 further supporting a role for this pathway in the development of etoposide-related leukemia. Of course, many of the genes invoked in this analysis (Table 2; Figure 4 ) have roles in additional pathways (apoptosis, signaling, cell cycle) that could impact leukemogenesis via alternative mechanisms.
We acknowledge that genome-wide approaches can fail to identify important genes. For instance, TPMT, GSTs, CYP3A4 and NQO1, 11, 12, 51 are candidate genes linked to the development of secondary leukemia, although none of these genes was represented on the 100K chip. However, for areas analyzed, the mapping arrays confirmed cytogenetic findings. In addition, the mapping arrays also detected LOH and copy number change in numerous regions that escaped detection by conventional cytogenetics.
In these secondary leukemia cases, in which the primary molecular defect has been thought to be the MLL gene rearrangement, there was little evidence for additional recurring acquired genomic abnormalities. These findings are consistent with the notion that rearrangement of MLL is nearly a sufficient 'hit' for leukemogenesis, consistent with our findings that MLL rearrangements in primary ALL also have few copy number alterations. 52 However, the additional genomic abnormalities that characterized the secondary leukemia cases were clustered in relatively few genes, which play critical roles in the focal adhesion, Wnt signaling and regulation of actin pathways. Using a combination of genome-wide approaches in a clinically based epidemiologic study, and an experimental laboratory approach, we have identified novel but plausible genetic variation that predisposes to secondary leukemia. Our findings provide new candidate genes for studying mechanisms of leukemogenesis, and illustrate how applying a genome-wide approach to both clinical and laboratory models can reveal novel pharmacogenetic and biologic targets.
